Very interesting R&D decision......by Endo which, I have to believe (even by default) means a higher priority, more focus, and more resources on the continued development of Urocidin...
On November 11, 2011, Endo Pharmaceuticals Holdings Inc. (the "Company") decided to terminate the development of its octreotide implant for the treatment of acromegaly. The decision was made after conducting an in-depth review of the Company's research and development activities, including an analysis of research and development priorities, focus and available resources for current and future projects and the commercial potential for the product.
See most today's 8-K form from Endo per link
https://phx.corporate-ir.net:80/phoenix.zhtml?c=123046&p=irol-sec
This makes Urocidin Endo's ONLY product in development that is now in phase III trials (and Urocidin is, of course in the part b of phase III after demonstrating solid/strong results in phase IIIa.
Look for the bar for octreotide implant (acromegaly) to be deleted shortly.
Also, see the PPT just presented by Endo and note the emphasis placed on Urology (slide 12 in second 8-k form, per above link)
A very interesting development! Have a good one, rg